FDAnews
www.fdanews.com/articles/81678-nabi-announces-successful-results-from-staphvax-study

NABI ANNOUNCES SUCCESSFUL RESULTS FROM STAPHVAX STUDY

October 14, 2005

Nabi Biopharmaceuticals has reported positive results from its StaphVAX (staphylococcus aureus polysaccharide conjugate vaccine) study, which was an open-label study testing the safety and immune response of three commercial scale lots of StaphVAX. StaphVAX was given to 354 healthy adults at three study sites in the U.S.

The data gathered from this study demonstrated that StaphVAX can elicit high levels of antistaphylococci antibodies, and that it can be consistently and successfully manufactured. The data also demonstrated that the manufacturing process is both well-controlled and reproducible.

StaphVAX is an investigational polysaccharide conjugate vaccine that presents a novel approach to the prevention of S. aureus infections. Nabi Biopharmaceuticals is developing StaphVAX for patients who are at high risk of S. aureus infections and who are able to respond to a vaccine by producing their own antibodies. StaphVAX is designed to stimulate a patient's immune system to produce antibodies to S. aureus for active, long-term protection from S. aureus Types 5 and 8, which are responsible for approximately 85 percent of all S. aureus infections.